Arbutus Biopharma Corp
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $10.7M | $1.5M | $23.3M | $15.0M | $15.5M | $14.1M | $16.8M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $62.7M | $61.3M | $51.5M | $38.7M | $21.5M | $18.0M | $20.1M |
| SG&A Expense | $16.1M | $39.4M | $26.4M | $8.7M | $5.5M | $8.1M | $6.4M |
| Operating Income | $-110.9M | $-491.6M | $-103.9M | $-33.4M | $-12.2M | $-12.9M | $-10.7M |
| Operating Margin | -1,036.7% | -32,973.8% | -446.5% | -223.6% | -78.6% | -91.8% | -63.6% |
| Interest Expense | $261.0K | $0 | $0 | — | — | — | — |
| Pretax Income | $-108.7M | $-489.2M | $-78.9M | $-38.8M | $-14.1M | — | — |
| Income Tax Expense | $-24.3M | $-105.0M | $-16.2M | $0 | $0 | — | — |
| Net Income | $-84.4M | $-384.2M | $-62.7M | $-38.8M | $-14.1M | $29.6M | $-10.1M |
| Net Margin | -788.9% | -25,765.5% | -269.5% | -259.7% | -90.9% | 209.9% | -60.0% |
| EPS (Basic) | $-1.56 | $-7.24 | $-1.38 | $-0.90 | $-0.46 | $1.08 | $-0.45 |
| EPS (Diluted) | $-1.56 | $-7.24 | $-1.38 | $-0.90 | $-0.46 | $1.04 | $-0.45 |
| Shares Outstanding (Basic) | 54.7M | 53.1M | 45.5M | 43.2M | 30.6M | 27.5M | 22.6M |
| Shares Outstanding (Diluted) | 54.7M | 53.1M | 45.5M | 43.2M | 30.6M | 28.6M | 22.6M |
| Dividends Per Share | — | — | — | — | — | — | — |